- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Tranexamic Acid Increases Complications Without Reducing Blood Transfusions in Liver Resection, HeLiX Trial Finds
![Tranexamic Acid Increases Complications Without Reducing Blood Transfusions in Liver Resection, HeLiX Trial Finds Tranexamic Acid Increases Complications Without Reducing Blood Transfusions in Liver Resection, HeLiX Trial Finds](https://medicaldialogues.in/h-upload/2024/07/31/750x450_245668-surgery-50-6.webp)
Canada: In a recent study published from the HeLiX randomized clinical trial, the use of tranexamic acid in patients undergoing liver resection for cancer-related conditions is both ineffective and potentially harmful. The trial's findings challenge the prior belief that tranexamic acid, a medication commonly used to reduce bleeding, would benefit patients undergoing complex liver surgeries.
The study, published in JAMA, revealed that tranexamic acid did not reduce bleeding or blood transfusion but increased perioperative complications among patients undergoing liver resection for a cancer-related indication.
"Within seven days of surgery, 16.3% of participants who received tranexamic acid required red blood cell (RBC) transfusions, compared to 14.5% of those who received a placebo. Additionally, the group treated with tranexamic acid experienced notably higher rates of perioperative complications compared to the placebo group, with an odds ratio of 1.28 indicating a significantly increased risk," the researchers reported.
Tranexamic acid is known for its antifibrinolytic properties, which help prevent excessive bleeding by inhibiting the breakdown of blood clots. It is known to reduce bleeding and the need for blood transfusions in various types of surgery, but its effectiveness in patients undergoing liver resection for cancer-related conditions remains uncertain. To fill this knowledge gap, Paul J. Karanicolas, Department of Surgery, University of Toronto, Toronto, Ontario, Canada, and colleagues aimed to investigate whether tranexamic acid reduces RBC transfusion within 7 days of liver resection.
For this purpose, the researchers conducted a multicenter randomized clinical trial from December 1, 2014, to November 8, 2022, at 10 hepatopancreaticobiliary sites in Canada and one site in the United States, with a 90-day follow-up. The study included a volunteer sample of 1,384 patients undergoing liver resection for cancer-related conditions, who met eligibility criteria and consented to randomization. Participants, clinicians, and data collectors were blinded to the treatment allocation.
The trial compared the effects of tranexamic acid, administered as a 1-gram bolus followed by a 1-gram infusion over 8 hours, with a matching placebo. 619 participants received tranexamic acid, while 626 received the placebo, starting at the anesthesia induction.
The primary outcome measure was the incidence of red blood cell transfusion within seven days of surgery.
The study revealed the following findings:
- The primary analysis included 1245 participants (mean age, 63.2 years; 39.8% female; 56.1% with a diagnosis of colorectal liver metastases).
- Perioperative characteristics were similar between groups.
- RBC transfusion occurred in 16.3% of participants in the tranexamic acid group and 14.5% in the placebo group (odds ratio, 1.15).
- Measured intraoperative blood loss (tranexamic acid, 817.3 mL; placebo, 836.7 mL) and total estimated blood loss over seven days (tranexamic acid, 1504.0 mL; placebo, 1551.2 mL) were similar between groups.
- Participants receiving tranexamic acid experienced significantly more complications than placebo (odds ratio, 1.28), with no significant difference in venous thromboembolism (odds ratio, 1.68).
Other trials that found no impact of tranexamic acid on RBC transfusion suggest that varying sources of bleeding may explain the differing results observed in previous studies. For example, the HALT-IT trial, which included 12,009 patients with acute gastrointestinal bleeding, found no effect of TXA on bleeding-related mortality. Additionally, a recent trial evaluating prophylactic TXA to prevent obstetrical hemorrhage following Cesarean delivery revealed no significant impact on maternal death or the need for blood transfusion.
Reference:
Karanicolas PJ, Lin Y, McCluskey SA, et al. Tranexamic Acid in Patients Undergoing Liver Resection: The HeLiX Randomized Clinical Trial. JAMA. Published online August 19, 2024. doi:10.1001/jama.2024.11783
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751